Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...

Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and ...

The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.